TY - JOUR
T1 - Polygenic risk scores for coronary artery disease and subsequent event risk amongst established cases
AU - Howe, Laurence J
AU - Dudbridge, Frank
AU - Schmidt, Amand F
AU - Finan, Chris
AU - Denaxas, Spiros
AU - Asselbergs, Folkert W
AU - Hingorani, Aroon D
AU - Patel, Riyaz S
N1 - Funding Information:
British Heart Foundation Intermediate Fellowship (Dr Patel, grant number FS/14/76/30933); National Institute for Health Research University College London Hospitals Biomedical Research Centre; British Heart Foundation grant number PG/18/5033837 to A.F.S.; University College London Hospitals National Institute for Health Research Biomedical Research Centre, European Union/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative 2 Joint Undertaking BigData@Heart grant no 116074 to F.W.A.; European Union’s Horizon 2020 research and innovation programme under the ERA-NET Co-fund action No. 01KL1802 (Druggable-MI-gene); Dutch Heart Foundation and Netherlands Organization for Health Research and Development (ZonMw). Professor Hingorani is a National Institute for Health Research Senior Investigator. The funder(s) of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.
Publisher Copyright:
© 2020 The Author(s). Published by Oxford University Press.
PY - 2020/5/28
Y1 - 2020/5/28
N2 - Background: There is growing evidence that polygenic risk scores (PRSs) can identify individuals with elevated lifetime risk of coronary artery disease (CAD). Whether they can also be used to stratify the risk of subsequent events among those surviving a first CAD event remain uncertain, with possible biological differences between CAD onset and progression, and the potential for index event bias. Methods: Using two baseline subsamples of UK Biobank: Prevalent CAD cases (N = 10 287) and individuals without CAD (N = 393 108), we evaluated associations between a CAD PRS and incident cardiovascular and fatal outcomes. Results: A 1 SD higher PRS was associated with an increased risk of incident myocardial infarction (MI) in participants without CAD (OR 1.33; 95% CI 1.29, 1.38), but the effect estimate was markedly attenuated in those with prevalent CAD (OR 1.15; 95% CI 1.06, 1.25) and heterogeneity P = 0.0012. Additionally, among prevalent CAD cases, we found an evidence of an inverse association between the CAD PRS and risk of all-cause death (OR 0.91; 95% CI 0.85, 0.98) compared with those without CAD (OR 1.01; 95% CI 0.99, 1.03) and heterogeneity P = 0.0041. A similar inverse association was found for ischaemic stroke [prevalent CAD (OR 0.78; 95% CI 0.67, 0.90); without CAD (OR 1.09; 95% CI 1.04, 1.15), heterogeneity P < 0.001]. Conclusions: Bias induced by case stratification and survival into UK Biobank may distort the associations of PRS derived from case-control studies or populations initially free of disease. Differentiating between effects of possible biases and genuine biological heterogeneity is a major challenge in disease progression research.
AB - Background: There is growing evidence that polygenic risk scores (PRSs) can identify individuals with elevated lifetime risk of coronary artery disease (CAD). Whether they can also be used to stratify the risk of subsequent events among those surviving a first CAD event remain uncertain, with possible biological differences between CAD onset and progression, and the potential for index event bias. Methods: Using two baseline subsamples of UK Biobank: Prevalent CAD cases (N = 10 287) and individuals without CAD (N = 393 108), we evaluated associations between a CAD PRS and incident cardiovascular and fatal outcomes. Results: A 1 SD higher PRS was associated with an increased risk of incident myocardial infarction (MI) in participants without CAD (OR 1.33; 95% CI 1.29, 1.38), but the effect estimate was markedly attenuated in those with prevalent CAD (OR 1.15; 95% CI 1.06, 1.25) and heterogeneity P = 0.0012. Additionally, among prevalent CAD cases, we found an evidence of an inverse association between the CAD PRS and risk of all-cause death (OR 0.91; 95% CI 0.85, 0.98) compared with those without CAD (OR 1.01; 95% CI 0.99, 1.03) and heterogeneity P = 0.0041. A similar inverse association was found for ischaemic stroke [prevalent CAD (OR 0.78; 95% CI 0.67, 0.90); without CAD (OR 1.09; 95% CI 1.04, 1.15), heterogeneity P < 0.001]. Conclusions: Bias induced by case stratification and survival into UK Biobank may distort the associations of PRS derived from case-control studies or populations initially free of disease. Differentiating between effects of possible biases and genuine biological heterogeneity is a major challenge in disease progression research.
UR - https://www.scopus.com/pages/publications/85085586259
U2 - 10.1093/hmg/ddaa052
DO - 10.1093/hmg/ddaa052
M3 - Article
C2 - 32219344
SN - 0964-6906
VL - 29
SP - 1388
EP - 1395
JO - Human molecular genetics
JF - Human molecular genetics
IS - 8
ER -